大鼠正中视前核注射血管紧张素Ⅱ(ANGⅡ)对某些肾脏功能指标的影响

目的：探讨大鼠正中视前核注射血管紧张素Ⅱ（ANGⅡ）对某些肾脏功能指标的影响。方法：健康雄性SD大鼠56只随机分为4组（n=14）：①人工脑脊液组：正中视前核（MnPO）先注射人工脑脊液（aCSF）0.25 μl,20 min后再注射0.25 μl,②血管紧张素Ⅱ组：MnPO先注射aCSF 0.25μl,20 min后再注射内含20 ng血管紧张素Ⅱ（AngⅡ）溶液0.25μl,③洛沙坦预处理组：MnPO先注射内含5μg洛沙坦（Losartan）溶液0.25μl,20 min后再注射20 ng血管紧张素Ⅱ溶液0.25μl,④洛沙坦组：MnPO先注射内含5μg洛沙坦溶液0.25μl,20 min后再注射aCSF 0.25μl。每组取7只大鼠在注射前、注射后20 min、40 min、60 min、120 min检测尿钠浓度,另7只大鼠注射1 h后处死动物,取肾脏,检测各组大鼠肾组织一氧化氮（NO）含量和一氧化氮合酶（NOS）活性。结果：52只大鼠进入结果分析,与人工脑脊液组相比,血管紧张素Ⅱ组肾脏NO与NOS活性升高,1 h肾排钠量明显升高;与洛沙坦预处理组相比,血管紧张素Ⅱ组肾脏NO与NOS活性升高,1 h肾排钠量也明显升高。结论：AngⅡ作用于MnPO后,肾促钠排泄反应增强,肾皮质NO水平升高,NOS活性增强,洛沙坦预处理可下调AngⅡ在肾脏诱导的上述变化。     

肾性和自发性高血压大鼠心肌肥大前后心肌Gαq/11含量的变化

目的 :探讨Gαq/11在不同原因所致心肌肥大中的变化。方法 :两肾一夹肾性高血压大鼠 (RHR)和自发性高血压大鼠(SHR)模型 ,测定动脉血压和心肌肥大指数 ,放免法测定心肌血管紧张素II(AngII)含量 ,免疫印迹法测定心肌Gαq/11含量。 结果 :RHR术后 1周动脉血压、心肌肥大指数及Gαq/11含量与假手术组无差异 ,心肌AngII含量显著升高 (P <0 .0 1) ;术后 8周上述各指标均较假手术组升高。 12周龄SHR动脉血压、心肌肥大指数和AngⅡ含量均较同龄WKY升高 (P均 <0 .0 1) ,但心肌Gαq/11含量却无明显变化 ;4周龄时上述各指标与同龄对照相比均无明显差异。 结论 :Gαq/11在肾性和自发性高血压心肌肥大中有不同变化。     

心房钠尿肽的中枢性心血管和肾效应

在麻醉大鼠观察了颈动脉、脊髓蛛网膜下腔和侧脑室内注射心房钠尿肽(Atrial natri-uretic peptide,ANP)后,血压,心率或/和尿量、尿钠和尿钾的变化,并观察了 ANP 对血管紧张素Ⅱ(AGⅡ)中枢效应的影响。结果如下:(1)在大鼠头部交叉循环条件下,经受血鼠颈总动脉内注射α-人心房钠尿多肽(α-human atrial natriurctic polypeptide,α-hANP)(15μg/kg)后,受血鼠平均动脉压(MAP)无改变,而供血鼠的 MAP 降低,⊿MAP为-2.4±0.84kPa(-18±6.3mmHg,P<0.05),(2)脊髓蛛网膜下腔注射心房肽,Ⅱ(AtriopeptinⅡ,APⅡ)(5μg/kg)对血压、心率和尿量无明显影响;(3)侧脑室注射 APⅡ(20μg/kg)后血压和心率无显著改变,尿量仅在注射后第30至50min 时显著增加,而尿钠无改变;(4)侧脑室注射 AGⅡ(1μg/kg),血压升高,⊿MAP 为1.3±0.17kPa(10±1.3mmHg,n=10,P<0.001)。注射1h 后,尿量增加106%(P<0.01),尿钠增加642%(P<0.01);(5)事先侧脑室注射 APⅡ(20μg/kg),2min 后再注入 AGⅡ(1μg/kg),AGⅡ的中枢升压效应不受影响,⊿MAP为1.5±0.25kPa(11±1.9mmHg,n=7,P<0.01),而尿量和尿钠的增值明显减小。以上结果表明,ANP 难于透过血脑脑脊血屏障,可能与其分子量较大有关。在静脉注射 ANP 所致降压效应中,似无中枢机制的参与。ANP 对 AGⅡ     

家兔孤束核联合亚核微量注射血管紧张素Ⅱ的心血管效应

在乌拉坦麻醉的家兔,向孤束核联合亚核(CNTS)微量注射血管紧张素Ⅱ(AⅡ)4μg平均动脉血压明显升高,心率减慢;切断双侧窦神经和减压神经后,AⅡ的升压作用更为显著,但心率几乎不再减少;AⅡ对血压和心率的作用不受预先向CNTS注射纳洛酮的影响;注射AⅡ也不影响动脉压力感受器反射的敏感性。这些结果表明:CNTS内小剂量注射AⅡ主要影响脑干内的血管运动神经元,而对控制心率的神经元无明显影响。     

卡托普利所致肾脏损害：肾小球入球动脉对血管紧张素Ⅱ反应和炎症信号的相关研究（英文）

卡托普利可表现出一定的肾毒性作用,主要是源于该药物会造成肾素的累积和血管紧张素Ⅱ (angiotensin Ⅱ, Ang Ⅱ)的逃逸。本研究主要目的是探究血管紧张素转换酶1抑制剂卡托普利是否通过改变肾入球动脉对Ang Ⅱ的反应,同时激活炎性信号通路而损伤肾脏。用卡托普利(每天60 mg/kg)喂养C57Bl/6小鼠四周,其中后两周用皮下植入Ang Ⅱ (400 ng/kg per min)微泵注射建立高血压小鼠模型。模型建成后,用PAS (periodic acid-Schiff)及Masson染色评估肾脏的病理改变,用FITC标记的菊粉清除率检测肾小球滤过率,用体外入球动脉灌注方式检测入球动脉对Ang Ⅱ反应,用试剂盒检测肾小球前小动脉(preglomerular arterioles)的过氧化氢、过氧化氢酶水平和血浆肾素水平,用RT-qPCR检测肾皮质转化生长因子β(transforming growth factor-β, TGF-β),环氧合酶-2 (cyclooxygenase-2, COX-2)和肾小球前小动脉血管紧张素受体mRNA表达水平。结果显示,与溶剂组小鼠相比,卡托...     

心房钠尿因子对麻醉家兔局部血流的影响

在42只麻醉家兔,观察了静脉注射心房肽Ⅱ(AtriopeptinⅡ,APⅡ)对局部血流量以及动脉内注射 AP Ⅱ 对局部血管阻力的影响。结果如下:(1)静脉注射 APⅡ(30μg/kg)5min后,平均动脉压(MAP)降低11.0±1.5mmHg(n=8,M±SE,下同),与溶剂对照组相比有明显差异(P相似文献   

家兔第四脑室内注射血管紧张素Ⅱ产生加压效应的机理

实验在53只乌拉坦(1g/kg)麻醉,肌肉麻痹,人工呼吸的家兔进行,(1)第四脑室微量注射5μg血管紧张素Ⅱ(AⅡ)使平均动脉血压升高,肾神经放电频率增加,心率减慢;但注射前先去除减压反射,心率就不出现减慢。(2)预先在第四脑室注射1μg哌唑嗪可减弱AⅡ的加压作用和阻断肾神经放电频率的增加,加用3μg育亨宾后,AⅡ的加压作用无进一步减弱。(3)但预先在第四脑室注射1μg哌唑嗪和10μl精氨酸加压素抗血清,就可完全抑制AⅡ的加压作用。结果提示:第四脑室注射的AⅡ具有中枢加压作用,此作用是通过增加外周血管阻力实现的,且由中枢α_1受体和加压素介导。     

乳酸菌发酵产品的降血压功能及其机制

1概述 血压是目前最为广泛的心血管疾病,据世界卫生组织（WHO）估计,全球患病人数已超过5亿.它是冠心病、脑卒死、心及肾功能衰竭的最主要发病因素,预防和治疗高血压将有助于降低心血管系统疾病的风险.高血压是由多方面因素引发的,如精神、神经、内分泌、遗传及血管紧张素转化酶（Angiotensin Ⅰ-converting enzyme,ACE）活性等,尤以ACE在血压调节过程中起关键作用.如图1所示,一方面,无活性的血管紧张素原在肾素的作用下转化为血管紧张素Ⅰ,血管紧张素Ⅰ在ACE的作用下转化为血管紧张素Ⅱ,血管紧张素Ⅱ能刺激血管收缩使血压升高,同时血管紧张素Ⅱ也能促使醛固酮分泌,直接对肾脏作用,引起纳储量和血容量增加也使血压升高.与此相反,缓激肽是降压物质,它能促使血管扩张和刺激扩血管物质前列腺素的合成增加,二者共同作用使血压下降.而在ACE的作用下,缓激肽分解成失活片断.如果人体内ACE活性过高,就会使血管紧张素Ⅱ生成增加,同时缓激肽被大大破坏,导致血压升高.     

大鼠脑室内注射ANGⅡ和ANGⅡ抗体对尿钠排出和肾皮质Na~+·K~+-ATPase的影响

在麻醉大鼠的侧脑室注射16pg血管紧张素Ⅱ(ANGⅡ),15min内出现尿钠增多的反应并持续90min,平均动脉血压保持稳定。肾皮质Na~+·K~+-ATPase活性(1.51±0.26μmolPi/mg Pro·h)显著低于侧脑室注射人工脑脊液的对照值(2.66±0.28μmol Pi/mg Pro·h,P<0.01),而侧脑室注射ANGⅡ抗体后5min内则出现尿钠减少的反应并持续135min。肾皮质Na~+·K~+-ATPase活性(3.61±0.34μmol Pi/mg Pro·h)显著高于对照值(P<0.05)。股静脉和脊髓蛛网膜下腔分别注射16pg ANGⅡ,均未出现尿钠增多的反应。结果表明,脑内的内源性ANGⅡ具有引起尿钠增多的作用;并提示这种作用可能与肾脏Na~+·K~+-ATPase活性的抑制有关。     

动脉压力感受性反射受损后血浆和心脏、肾脏组织AngⅡ含量的变化

既往的研究表明,动脉压力感受性反射（ABR）功能下降在高血压靶器官损伤中起独立作用。为进一步研究ABR功能下降致器官损伤的可能机制,实验采用去窦弓神经（SAD）大鼠作为ABR受损的动物模型,分别测定清醒、自由活动状态下SAD及对照的假手术组大鼠24h动脉血压、心率、血压波动性（BPV）及心率波动性（HRV）。并采用放免法测定血浆、心脏和肾脏组织的血管紧张素Ⅱ（AngⅡ）含量。结果发现,SAD术后1周大鼠的24h平均收缩压（SBP）、舒张压（DBP）均显著高于对照组及术后18周的慢性期SAD大鼠。SAD术后18周,24h平均SBP、DBP及HR与假手术对照组均无显著差异;24h收缩压波动性（SBPV）和舒张压波动性（DBPV）均显著高于对照组大鼠。SAD大鼠术后1周的血浆、心脏和肾脏组织的AngⅡ含量及术后18周的血浆AngⅡ水平与对照组之间相比无显著差异。而在术后慢性期（18周）,SAD大鼠的心肌及肾组织AngⅡ含量显著高于假手术对照组大鼠。在术后18周时,接受慢性应激刺激的SAD大鼠,其血浆、心肌及肾组织中AngⅡ水平显著高于同处应激状态下的假手术对照组大鼠及未接受应激刺激的SAD大鼠。这些结果表明,SAD术后急性期血压增高,但在慢性期平均血压并无增高,仅BPV增高;慢性期心、肾组织内AngⅡ的分泌增加。在慢性期接受应激可致AngⅡ过度分泌,上述结果提示,BPV增高和心、肾组织AngⅡ含量升高与SAD大鼠发生心脏、肾脏等器官损害有关。     

Regional blood flows and cardiac hemodynamics in renovascular and mineralocorticoid hypertensive rats

Regional blood flows and cardiac hemodynamics were studied in 3 models of hypertensive rats: one-kidney DOC-saline, one-kidney, one-clip and two-kidney, one-clip hypertension and in normotensive control rats. All hypertensive models were characterized by increased peripheral vascular resistance and normal cardiac output. Coronary and cerebral blood flows varied among the hypertensive models but did not significantly differ from the normotensive rats. However, coronary blood flow of one-kidney, one-clip rats (8.4 +/- 1.3 ml X min-1 X g-1) was significantly higher than that of the two-kidney one-clip rats (6.5 +/- 1.2 ml X min.-1 X g-1, P less than 0.05). Cerebral blood flow of DOC-saline rats was lower than that of two-kidney one-clip or one-kidney one-clip renovascular rats. Renal blood flows of the unclipped kidney of two-kidney renovascular rats (3.77 +/- 0.85 ml X min-1 X g-1) and DOC-saline rats (2.95 +/- 0.83 ml X min-1 X g-1) were significantly lower than those of normotensive rats (5.92 +/- 1.16 ml X min-1 X g-1, P less than 0.05). In conclusion, although vascular resistance becomes elevated in all models of experimental hypertension, regional vascular resistance and blood flow distribution may differ depending on the vasoconstrictor mechanisms that participate in each model.     

Reductions in blood pressure after acute exercise by hypertensive rats

Postexercise reductions in blood pressure at rest have been reported for hypertensive subjects. To determine whether post-exercise hypotension would occur in spontaneously hypertensive rats and to test the hypothesis that any reductions would result because of decreases in regional vascular resistances, hypertensive rats (n = 19) were instrumented with indwelling arterial catheters and Doppler probes to measure regional blood flows from the iliac, superior mesenteric, and renal arteries. Data were collected from animals who performed a 20- and a 40-min treadmill test at between 60 and 70% of their maximum O2 uptake. When the animals ran for 20 min, there was a pre- to postexercise drop in mean arterial pressure (MAP) from 158 +/- 3.6 to 150 +/- 3.6 mmHg (P less than 0.05), which was recorded 30 min after the exercise had ceased. The pre- to postexercise reduction in MAP after 40 min of treadmill running was from 154 +/- 3.1 to 138 +/- 3.0 mmHg (P less than 0.05) as recorded 30 min postexercise. Postexercise heart rate was significantly lower after the 40-min exercise bout, from a preexercise mean of 351 +/- 3 beats/min to 324 +/- 5 beats/min 30 min after the treadmill had stopped. Surprisingly, marked pre- to postexercise reductions in regional vascular resistance were not observed in either the iliac, superior mesenteric, or renal vascular beds. These data demonstrated the existence of postexercise hypotension in genetic hypertensive rats and suggested that reductions in cardiac output were the primary hemodynamic mechanism for this finding.     

心钠素对卒中易感型自发性高血压大鼠血浆和脑组织加压素的影响

为研究心钠素(ANF)和精氨酸加压素(AVP)的相互作用在原发性高血压发病中的意义,对卒中易感型自发性高血压大鼠(SHRsp)和对照大鼠(WKY)侧脑室(icv)或静脉(iv)注射人ANF-(99-126)观察其对血浆、下丘脑和垂体AVP含量以及平均动脉压(MAP)和尿量(UV)、尿钠(U_(Na)V)排泌的影响。静脉注射ANF后10min,SHRsp和WKY大鼠的MAP分别下降9.4％和12.2％(P<0.05),UV分别增加9和20倍(P<0.01),U_(Na)V增加16和29倍(P<0.01)。侧脑室注射ANF对两种大鼠的MAP、UV和U_(Na)V排泌均无明显作用。静脉或侧脑室注射ANF均使两种大鼠的血浆AVP水平明显下降,其中SHRsp的血浆AVP浓度下降程度(iv,-58％;icv,-31％)弱于WKY大鼠(iv,-80％;icv,-65％),下丘脑AVP含量在两种大鼠中都明显增加,而垂体AVP含量无明显变化。 结果表明,人ANF-(99-126)有明显的抑制AVP释放和降压、利尿、利纳作用,而SHRsp对这些作用的敏感性都降低,提示SHRsp对ABF的反应减弱可能在自发性高血压大鼠的发病中具有一定的意义。     

Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy.

STUDY OBJECTIVE--To assess whether long term inhibition of angiotensin converting enzyme with captopril and frusemide or bendrofluazide protects kidney function in diabetic nephropathy. DESIGN--Non-randomised controlled before-after trial of matched hypertensive insulin dependent diabetics with nephropathy treated with captopril and frusemide or bendrofluazide. SETTING--Outpatient diabetic clinic in tertiary referral centre. PATIENTS--Treatment group of 18 hypertensive insulin dependent diabetics with nephropathy (mean age 33), who had not been treated previously. Control group of 13 patients (mean age 32) fulfilling the same entry criteria from a prospective study. INTERVENTIONS--Treatment group was given daily captopril 37.5-100.0 mg and frusemide (mean) 98 mg (10 patients) or bendrofluazide (mean) 4 mg (seven). Treatment was continued for about two and a half years. Controls were not treated. END POINT--Measurement of arterial blood pressure, albuminuria, and glomerular filtration. MEASUREMENTS AND MAIN RESULTS--Baseline values were identical in treated and untreated groups respectively: mean blood pressure 146/93 (SE 3/1) mm Hg v 137/95 (2/1) mm Hg; geometric mean albuminuria 982 (antilog SE 1.2) micrograms/min v 936 (1.2) micrograms/min; and mean glomerular filtration rate 98 (SE 5) ml/min/1.73 m2 v 96 (6) ml/min/1.73 m2. Mean arterial blood pressure fell by 8.7 (1.3) mm Hg with captopril and rose by 6.6 (1.5) mm Hg in controls, (p less than 0.001); Albumin excretion decreased to 390 (1.1) micrograms/min with captopril and rose to 1367 (1.3) micrograms/min in controls (p less than 0.001). The rate of decrease in glomerular filtration rate was lower with captopril (5.8 (0.7) ml/year v 10.0 (1.3) ml/year) (p less than 0.01). Rate of fall in glomerular filtration rate and mean arterial blood pressure were significantly correlated (n = 31, r = 0.37, p less than 0.05). CONCLUSIONS--Captopril is a valuable new drug for treating hypertension in insulin dependent diabetics with nephropathy.     

Digitalis attenuates arterial hypertrophy in experimental hypertension

Several investigators have reported that digitalis administration reduces cardiac hypertrophy in rats with experimental hypertension. To determine whether digitalis similarly affects growth of arteries, we studied young (5- to 14-week-old), male, one-kidney, one-clip hypertensive rats (1K1C; n = 14) and one-kidney normotensive control rats (1K; n = 26). Half of the rats received digoxin (150 mg/kg body wt/day) in chow starting 1-2 weeks before clipping (1K1C-D; 1K-D); the other half were pair-fed (1K1C-C; 1K-C). Serum digoxin levels averaging 488 ng/ml were documented in rats receiving digoxin. After 3-5 weeks of hypertension (conscious tail blood pressures), and at a similar time period in normotensive control rats, we measured direct femoral arterial pressure and weighed standardized segments of the thoracic aorta. At sacrifice body weights of the four groups did not differ. In the one-kidney control rats, mean +/- SE femoral arterial pressure (1K-D, 108 +/- 3; 1K-C, 111 +/- 4, mm Hg), thoracic aortic dry weight (1K-D, 36.6 +/- 0.6; 1K-C, 36.2 +/- 1.1. mg/kg body wt), and aortic water content (1K-D, 62.7 +/- 0.4; 1K-C, 62.4 +/- 0.4, % wet weight) did not differ between rats receiving or not receiving digoxin, respectively. As compared with pooled normotensive control rats, femoral arterial pressure (1K1C-D, 165 +/- 8; 1K1C-C, 153 +/- 5), aortic water content (1K1C-D, 64.8 +/- 0.4; 1K1C-C, 64.9 +/- 0.5), and aortic weight (1K1C-D, 44.8 +/- 2.1; 1K1C-C, 50.1 +/- 1.6) were increased (P less than 0.001) in the one-kidney, one-clip rats, on or off digoxin. Comparison of hypertensive rats receiving to those not receiving digoxin revealed no differences in arterial pressure or aortic water content, but aortic growth was significantly attenuated (-41%, P = 0.02) in the hypertensive rats receiving digoxin. These results provide evidence that digoxin reduces hypertensive arterial growth by a mechanism that does not affect normal growth.     

Chronic blockade of brain "ouabain" prevents sympathetic hyper-reactivity and impairment of acute baroreflex resetting in rats with congestive heart failure

In rats with congestive heart failure (CHF) post myocardial infarction (MI) acute blockade of brain "ouabain" reverses sympathetic hyperactivity and chronic blockade prevents the desensitization of baroreflex function. This study was conducted to determine: i) if chronic blockade of brain "ouabain" maintains normal sympathetic reactivity; and ii) if acute baroreflex resetting (another parameter of baroreflex function) also becomes impaired, and if so, does brain "ouabain" contribute to impairment in acute baroreflex resetting. CHF post MI was induced by acute coronary artery ligation in Wistar rats. Animals were treated with 200 microg x day(-1) i.c.v. or i.v. Fab fragments (which bind brain "ouabain" with high affinity), or treated with 200 microg x day(-1) i.c.v. gamma-globulins (control group). The length of treatment was 0.5-8 weeks or 4-8 weeks post MI. At 8 weeks mean arterial pressure (MAP), central venous pressure (CVP), heart rate (HR), and renal sympathetic nerve activity (RSNA) were recorded in concious rats at rest and in response to: i) air-jet stress, ii) i.c.v. guanabenz (an alpha2-adrenoceptor agonist), and iii) a 30 min i.v. infusion of nitroprusside (NP). Excitatory responses to air stress and inhibitory responses to guanabenz of MAP, HR, and RSNA were significantly enhanced in rats with CHF versus the sham-operated treated group. This enhancement was prevented in the CHF group treated with i.c.v., but not i.v., Fab. Nitroprusside induced a sustained decrease in MAP (approximately 25 mmHg) and a transient decrease in CVP. Heart rate and RSNA increased significantly within 1 min of beginning the infusion. The peak increases as well as the product of changes in MAP-HR and RSNA-HR were significantly smaller in rats with CHF treated with gamma-globulins versus sham rats and versus CHF rats treated with i.c.v. Fab. In sham-operated rats and CHF rats treated with i.c.v. Fab, RSNA and HR began to decrease within 3-4 min of beginning the NP infusion and had returned to baseline by 20 min. In contrast, RSNA and HR remained increased throughout the infusion in the CHF rats treated with gamma-globulins. These data indicate that in rats with CHF acute resetting of the arterial baroreflex in response to a lower BP becomes impaired, and chronic blockade of brain "ouabain" prevents both this change in baroreflex resetting as well as sympathetic hyperactivity.     

心房钠尿多肽对麻醉大鼠血压和肾神经传出放电的影响

本实验观察了心房肽Ⅱ(Atriopeptin Ⅱ,APⅡ)对麻醉大鼠血压(AP)、心率(HR)和肾交感神经传出放电(RSNA)的影响,并与硝普钠对 AP 和 RSNA 的影响作比较。结果如下:(1)缓冲神经完整和迷走神经完整条件下(n=12)静脉注射 APⅡ(50μg/kg)后,动脉收缩压(SAP)降低23.0±1.66 mmHg(Μ±SE,p<0.001),HR 减慢9±3.5b/min(p<0.05),RSNA 降低4.89±2.95%(P>0.05)。迷走神经切断后,静脉注射 APⅡ引起的~⊿SAP 虽有所减小,但与切断迷走神经前的反应比较,无统计学意义,HR 减慢不再出现,而 RSNA 则有所增加;(2)缓冲神经切断和迷走神经完整条件下(n=7),静脉注射 APⅡ时 SAP 降低27.4±3.25mmHg(P<0.001),HR 减慢13±3.1b/min(P<0.01),RSNA 降低11.67±1.95%(P<0.001)。切断迷走神经后,静脉注射 APⅡ引起的 SAP 降低程度有明显減小(P<0.01),HR减慢不再出现,RSNA 则反而增加(3)无论在迷走神经完整还是切断条件下,静脉注射硝普钠(n=6) SAP 均明显降低,同时伴有 RSNA 的反射性增加。以上结果表明:APⅡ的降压效应,部分是通过迷走神经传入纤维;在切断缓冲神经条件下,APⅡ可经由迷走神经传入纤维的激活而反射地抑制 RSNA。     

Differential cardiovascular effects of central clonidine and B-HT 920 in conscious rats

The effect of intracerebroventricular (i.c.v.) injection of the alpha 2-adrenoceptor agonists clonidine and B-HT 920 on mean arterial pressure (MAP), heart rate (HR), and plasma concentrations of noradrenaline and adrenaline was examined in conscious unrestrained rats. The injection of 1.0 microgram clonidine significantly decreased MAP and slightly decreased HR. Plasma noradrenaline and adrenaline levels were slightly but not significantly decreased after the injection of 1 microgram clonidine. In contrast, the injection of 0.1-10.0 micrograms B-HT 920 increased MAP and decreased HR. Plasma noradrenaline and adrenaline levels were slightly increased after the injection of the 1- and 10-micrograms doses. The i.c.v. injection of the alpha 2-antagonist rauwolscine slightly but not significantly increased MAP and plasma noradrenaline and adrenaline levels. The responses to i.c.v. injection of clonidine and B-HT 920 were not changed by prior administration of rauwolscine. Neither the pressor response to B-HT 920 nor the depressor response to clonidine was abolished by rauwolscine, suggesting that neither response was mediated by alpha 2-adrenoceptors.     

Effect of a chronic infusion of atrial natriuretic peptide on sodium balance in normotensive and two-kidney, one-clip hypertensive rats

We have previously found that chronic infusion of atrial natriuretic peptide (ANP) decreased mean arterial pressure (MAP) by 16% in two-kidney, one-clip (2K-1C) hypertensive rats, and we hypothesized that natriuresis might be modified through the pressure-natriuresis mechanism. We therefore decided to evaluate sodium balance in 2K-1C rats infused with ANP (0.5 micrograms/h for 4 days). The ANP infusion to the 2K-1C rats induced a significant decrease in MAP from 171 +/- 3 to a minimum value of 147 +/- 6 mm Hg after 2 days of treatment (p less than 0.001). Sodium excretion fell from 2,536 +/- 60 to 2,047 +/- 86 (p less than 0.001) and 2,211 +/- 96 mu Eq/24 h (p less than 0.05) by days 1 and 2 of ANP administration. Furthermore, fractional excretion of sodium intake decreased from 99.1 +/- 1.5 to 81.1 +/- 2.9 (p less than 0.001), 84.1 +/- 2.6 (p less than 0.05) and 85.9 +/- 5.15% (p less than 0.05) by days 1, 2 and 3 of ANP infusion, respectively, returning to basal values thereafter. The administration of vehicle (0.9% NaCl) did not induce any significant change in 2K-1C hypertensive rats. The infusion of either vehicle or the same dose of ANP to normotensive rats (0.5 micrograms/h, for 4 days) did not modify sodium balance throughout the experiment. These results strongly suggest that the ANP-induced decrease in MAP might be responsible for the transitory sodium retention observed in 2K-1C hypertensive rats during the administration of the peptide.